A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT)

• DOI: 10.3389/fonc.2024.1385685
• Publication Date: 2024-09-04T05:01:32Z
• Authors: Lev Demidov; Galina Kharkevich; Natalia Petenko; Vladimir Moiseenko; Svetlana Protsenko; Tatiana Semiglazova; Anastasia Zimina; Nadezhda Kovalenko; Natalia Fadeeva; Dmitry Kirtbaya; Igor Belogortsev; Denis Tantsyrev; Svetlana Odintsova; Alfia Nesterova; Karina Vorontsova; Yulia Makarycheva; Yulia Linkova; Arina Zinkina-Ori...; Anna Siliutina; Irina Sorokina; Daria Liaptseva; Vladimir Chistyakov; Anton Lutsky
• Keywords: PD-1 inhibitor; prolgolimab; Oncology; melanoma; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; immunotherapy; fixed dose; RC254-282

Prolgolimab is the first Russian PD-1 inhibitor approved for first-line treatment of unresectable or metastatic melanoma and advanced non-small cell lung cancer. It was in two weight-based regimens 1 mg/kg Q2W 3 Q3W, but because re-evaluation dosing paradigm, studying a fixed-dose regimen considered perspective.